QP Investigational medicinal products - eLearning knowledge reinforcement

2.00 Hour/s

eLearning

The focus of our QP Knowledge Reinforcement modules, is to provide a means for Trainee QPs to review the key information from the course content previously covered in the Tutor led course (whether delivered by RSSL or another supplier) and then test their knowledge.


The eLearning QP Knowledge Reinforcement module for Investigational Medicinal Products reviews 5 key sections from the tutor led course and 72 questions, to test your knowledge and ensure you know the subject matter, ready for your Viva.


There are two elements to each section :


  • Content review
  • Assessment/Questionnaire

The assessment/questionnaire is based on a mixture of question styles. You are required to get 80% of the questions correct and have 3 attempts to do so, after which you will be asked to take the section and the assessment again.


The eLearning QP Knowledge Reinforcement module for Active Pharmaceutical Ingredients, is suitable for any Trainee QPs that have previously attended an Investigational Medicinal Products, Tutor led course (whether delivered by RSSL or another supplier) and want to test their knowledge in readiness for their Viva.

The module covers the following content and questions related to the following topics:

  • Clinical Trial laws and guidelines
  • Clinical Trial roles & responsibilities
  • Clinical Trial authorisation and conduct
  • Manufacturing of IMPs for clinical trials
  • QP certification and IMP supply

    By the end of the module, QP trainees will have reinforced their knowledge on the following topics:

    • Clinical Trial laws and guidelines
    • Clinical Trial roles & responsibilities
    • Clinical Trial authorisation and conduct
    • Manufacturing of IMPs for clinical trials
    • QP certification and IMP supply
£ 170

ex VAT

Related course

Istock 1355977307

QP investigational medicinal products course

All QPs need to understand the different Good Manufacturing Practice (GMP) requirements for commercial and Investigational Medicinal Products (IMPs), and the unique additional GMP requirements for IMPs.